Skip to content

Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa

Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04035174
Acronym
EOLoa
Enrollment
0
Registered
2019-07-29
Start date
2022-09-01
Completion date
2023-03-30
Last updated
2025-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnoses Disease, Loiasis, Neglected Diseases, Onchocerciasis

Keywords

Health Public

Brief summary

This study aims at evaluating the diagnosis performances of the LTS-2 DEC patch for onchocerciasis compared to the gold standard which are the skin snips. This study will be conducted in Cameroon in two different areas : Ngog-Mapubi and Bafia Health Districts (one area only endemic for onchocerciasis, and one area endemic for both loiasis and onchocerciasis).

Interventions

DIAGNOSTIC_TESTLTS-2 DEC patch

After 24 hours, the patch will be removed, and then the reaction of the skin under the device will be assessed : no reaction, weak reaction (\< 50% skin surface under the patch), medium reaction (\> 50% skin surface under the patch), and important reaction (reaction on all the surface of the skin under the patch).

DIAGNOSTIC_TESTSkin snips

Regarding skin snips, a reading will be done at 24 hours after incubation of the skin in saline serum during 24 hours.

Sponsors

Center for Research on Filariasis and Other Tropical Diseases, Cameroon
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)

Masking description

Results from LTS-2 patch will be immediately known by both participant and investigators ; but results from skin snips will be masked both for participant and investigators.

Intervention model description

Each participant will have both a LTS-2 patch applied on the skin and a skin snip performed.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* All voluntary adults

Exclusion criteria

* General acute infection (temperature ≥ 38,5°C) * Impaired general condition * Ivermectin taken in the 6 last months * Known allergies to one of the component of the patch * Dermatological acute infection (bacterial, atopic, prurigo, or zona)

Design outcomes

Primary

MeasureTime frameDescription
Tolerability of the patch24 hoursProportion of individuals having developed a generalized Mazzotti's reaction
Feasibility of the patch24 hoursProportion of individuals for whom the patches are spontaneously removed from the skin during the 24 hours.

Secondary

MeasureTime frameDescription
Diagnosis performances24 hoursAssessment of the sensibility, specificity, and predictive values of the LTS-2 DEC patch compared to the results from the skin snips.
Loiasis and cross-reactivity assessment24 hoursLoiasis impact of the diagnosis performances of the LTS-2 DEC patch. Loiasis will be assessed with thick blood smears and a microscopic examination ; and with PCR in the skin snips
Semi-quantitative scoring of the LTS-2 DEC patch results24 hoursRelationship between the number of microfilariae of O. volvulus and the skin reaction under the patch (0 no reaction, 1: \< 50% of the skin under the patch, 2: \>50% of the skin under the patch, and 3: reaction under all the skin surface of the patch)

Countries

Cameroon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026